Abstract
Liver dysfunction is associated with adverse events in infective endocarditis (IE). However, few studies have explored the predictive value of conjugated bilirubin (CB) in IE. We aimed to investigate the nature of the link between CB and adverse prognosis in patients with IE. Consecutive patients with IE between January 2009 and July 2015 were enrolled. Multivariate analysis was performed to confirm whether CB was an independent risk factor for adverse outcomes. In all, 1010 patients were included and divided into two groups according to admission CB level (μmol/L): normal (≤ 7.0, n = 820) and elevated (> 7.0, n = 190) CB groups. In-hospital mortality (5.0% vs. 22.1%, p < 0.001) and major adverse cardiac events (16.8% vs. 36.3%, p < 0.001) were significantly higher in patients with increased CB. A possible J-shaped relationship was found between CB and in-hospital events. Further, CB had more predictive power than total bilirubin in predicting in-hospital death (AUC 0.715 vs. 0.674, p = 0.010). Elevated CB was an independent predictor of in-hospital death (adjusted OR = 2.62, 95%CI 1.40–4.91, p = 0.003). Moreover, CB (increment 1 μmol/L) was independently associated with higher long-term mortality. Kaplan–Meier curves indicated that patients with elevated CB were associated with higher cumulative rate of long-term death (log-rank = 21.47, p < 0.001). CB, a biomarker of liver function, was a relatively powerful predictor of in-hospital and long-term adverse prognosis of IE and could likely comprise a novel risk evaluation strategy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Cahill TJ, Baddour LM, Habib G et al (2017) Challenges in infective endocarditis. J Am Coll Cardiol 69:325–344
Di Mauro M, Dato GMA, Barili F et al (2017) A predictive model for early mortality after surgical treatment of heart valve or prosthesis infective endocarditis. The EndoSCORE. Int J Cardiol 241:97–102
Wei XB, Liu YH, He PC et al (2017) The impact of admission neutrophil-to-platelet ratio on in-hospital and long-term mortality in patients with infective endocarditis. Clin Chem Lab Med 55:899–906
Green RM, Flamm S (2002) AGA technical review on the evaluation of liver chemistry tests. Gastroerology 123:1367–1384
Whitehead MW, Hainsworth I, Kingham JG (2001) The causes of obvious jaundice in South West Wales: perceptions versus reality. Gut 48:409–413
Akboga MK, Canpolat U, Sahinarslan A et al (2015) Association of serum total bilirubin level with severity of coronary atherosclerosis is linked to systemic inflammation. Atherosclerosis 240:110–114
Kim DE, Lee Y, Kim M, Lee S, Jon S, Lee SH (2017) Bilirubin nanoparticles ameliorate allergic lung inflammation in a mouse model of asthma. Biomaterials. 140:37–44
Patel JJ, Taneja A, Niccum D, Kumar G, Jacobs E, Nanchal R (2015) The association of serum bilirubin levels on the outcomes of severe sepsis. J Intensive Care Med 30:23–29
Zhai R, Sheu CC, Su L et al (2009) Serum bilirubin levels on ICU admission are associated with ARDS development and mortality in sepsis. Thorax 64:784–790
Diab M, Sponholz C, von Loeffelholz C et al (2017) Impact of perioperative liver dysfunction on in-hospital mortality and long-term survival in infective endocarditis patients. Infection 45:857–866
Li JS, Sexton DJ, Mick N et al (2000) Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 30:633–638
Ma YC, Zuo L, Chen JH et al (2006) Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 17:2937–2944
Idelman G, Smith DLH, Zucker SD (2015) Bilirubin inhibits the up-regulation of inducible nitric oxide synthase by scavenging reactive oxygen species generated by the toll-like receptor 4-dependent activation of NADPH oxidase. Redox Biol 5:398–408
Overhaus M, Moore BA, Barbato JE, Behrendt FF, Doering JG, Bauer AJ (2006) Biliverdin protects against polymicrobial sepsis by modulating inflammatory mediators. Am J Physiol Gastrointest Liver Physiol 290:G695–G703
Keshavan P, Deem TL, Schwemberger SJ, Babcock GF, Cook-Mills JM, Zucker SD (2005) Unconjugated bilirubin inhibits VCAM-1-mediated transendothelial leukocyte migration. J Immunol 174:3709–3718
Nikolaou M, Parissis J, Yilmaz MB et al (2013) Liver function abnormalities, clinical profile, and outcome in acute decompensated heart failure. Eur Heart J 34:742–749
Samsky MD, Patel CB, DeWald TA et al (2013) Cardiohepatic interactions in heart failure: an overview and clinical implications. J Am Coll Cardiol 61:2397–2405
Cogger VC, Fraser R, Le Couteur DG (2003) Liver dysfunction and heart failure. Am J Cardiol 91:1399
van Deursen VM, Edwards C, Cotter G et al (2014) Liver function, in-hospital, and post-discharge clinical outcome in patients with acute heart failure-results from the relaxin for the treatment of patients with acute heart failure study. J Card Fail 20:407–413
Poelzl G, Ess M, Mussner-Seeber C, Pachinger O, Frick M, Ulmer H (2012) Liver dysfunction in chronic heart failure: prevalence, characteristics and prognostic significance. Eur J Clin Investig 42:153–163
Chand N, Sanyal AJ (2007) Sepsis-induced cholestasis. Hepatology 45:230–241
Peres BD, Melot C, Lopes FF, Nguyen BV, Vincent JL (2002) The Multiple Organ Dysfunction Score (MODS) versus the Sequential Organ Failure Assessment (SOFA) score in outcome prediction. Intensive Care Med 28:1619–1624
Ferreira FL, Bota DP, Bross A, Melot C, Vincent JL (2001) Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA 286:1754–1758
Ostrowski S, Kasielski M, Kordiak J, Zwolinska A, Wlodarczyk A, Nowak D (2013) Myocardial oxidative stress in patients with active infective endocarditis. Int J Cardiol 167:270–276
Wang WW, Smith DL, Zucker SD (2004) Bilirubin inhibits iNOS expression and NO production in response to endotoxin in rats. Hepatology 40:424–433
Lang E, Gatidis S, Freise NF et al (2015) Conjugated bilirubin triggers anemia by inducing erythrocyte death. Hepatology 61:275–284
Okada A, Sugano Y, Nagai T et al (2017) Usefulness of the direct and/or total bilirubin to predict adverse outcomes in patients with acute decompensated heart failure. Am J Cardiol 119:2035–2041
Bohmer T, Kjekshus E, Nitter-Hauge S (1994) Studies on the elimination of bilirubin pre-operatively in patients with mitral valve disease. Eur Heart J 15:10–16
Funding
This study was supported by Medical Science and Technology Research Funding of Guangdong (grant no.: A2019409).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
All patients provided written informed consent before inclusion. This research was approved by the ethics committee of Guangdong Provincial People’s Hospital.
Disclaimer
The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The work was not funded by any industry sponsors. All authors agreed to submit the manuscript for publication.
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Xue-biao Wei, Yu Wang, and Yuan-hui Liu are considered co-first authors.
Rights and permissions
About this article
Cite this article
Wei, Xb., Wang, Y., Liu, Yh. et al. Effect of conjugated bilirubin on clinical outcomes in infective endocarditis. Eur J Clin Microbiol Infect Dis 38, 2259–2266 (2019). https://doi.org/10.1007/s10096-019-03670-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10096-019-03670-4